Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma

Val Lowe, Mary E. Hebert, Mitchell S. Anscher, R. Edward Coleman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: Following radiation therapy for bronchogenic carcinoma, increased FDG accumulation within the irradiated tissue can be identified. This finding has not been well characterized. Therefore, we retrospectively evaluated the time course, frequency, and intensity of increased FDG uptake over a one-year period in patients who had been treated with radiation therapy. Materials and Methods: Serial FDG-PET studies (n = 38) were performed in patients (n = 12) with bronchogenic carcinoma before and after radiation therapy. Regions of interest (ROIs) were placed in the chest wall and activity concentrations of posttherapy studies were compared to pretherapy studies. FDG uptake was also described qualitatively relative to mediastinal activity (1-4 scale) by two observers blinded from clinical information. Results: Chest wall radiation port ROI uptake was 18% higher in the 2-month (P = 0.08), 40% higher in the 6-month (P = 0.003), and 32% higher in the 12-month (P = 0.04) posttherapy studies than in non-port ROIs. In 6 patients that clinically had radiation-induced chest wall fibrosis or pneumonitis, visual interpretation identified abnormal chest wall or pleural region FDG uptake in 5/6. In 2/6 patients without clinical chest wall fibrosis, abnormal, chest wall FDG uptake was seen. Conclusions: Radiation therapy occasionally causes modestly increased soft tissue FDG uptake within irradiated soft tissue in patients being treated for bronchogenic carcinoma, which persists for up to one year after therapy.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalClinical Positron Imaging (Netherlands)
Volume1
Issue number3
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Bronchogenic Carcinoma
Fluorodeoxyglucose F18
Thoracic Wall
Radiotherapy
Fibrosis
Radiation
Pneumonia

Keywords

  • F-18 fluorodeoxyglucose (FDG)
  • Lung neoplasms
  • Positron emission tomography (PET)
  • Therapeutic radiology
  • Treatment planning

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma. / Lowe, Val; Hebert, Mary E.; Anscher, Mitchell S.; Coleman, R. Edward.

In: Clinical Positron Imaging (Netherlands), Vol. 1, No. 3, 1998, p. 185-191.

Research output: Contribution to journalArticle

@article{a6c2b4b48b3b4dad968577bf75c1c09a,
title = "Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma",
abstract = "Purpose: Following radiation therapy for bronchogenic carcinoma, increased FDG accumulation within the irradiated tissue can be identified. This finding has not been well characterized. Therefore, we retrospectively evaluated the time course, frequency, and intensity of increased FDG uptake over a one-year period in patients who had been treated with radiation therapy. Materials and Methods: Serial FDG-PET studies (n = 38) were performed in patients (n = 12) with bronchogenic carcinoma before and after radiation therapy. Regions of interest (ROIs) were placed in the chest wall and activity concentrations of posttherapy studies were compared to pretherapy studies. FDG uptake was also described qualitatively relative to mediastinal activity (1-4 scale) by two observers blinded from clinical information. Results: Chest wall radiation port ROI uptake was 18{\%} higher in the 2-month (P = 0.08), 40{\%} higher in the 6-month (P = 0.003), and 32{\%} higher in the 12-month (P = 0.04) posttherapy studies than in non-port ROIs. In 6 patients that clinically had radiation-induced chest wall fibrosis or pneumonitis, visual interpretation identified abnormal chest wall or pleural region FDG uptake in 5/6. In 2/6 patients without clinical chest wall fibrosis, abnormal, chest wall FDG uptake was seen. Conclusions: Radiation therapy occasionally causes modestly increased soft tissue FDG uptake within irradiated soft tissue in patients being treated for bronchogenic carcinoma, which persists for up to one year after therapy.",
keywords = "F-18 fluorodeoxyglucose (FDG), Lung neoplasms, Positron emission tomography (PET), Therapeutic radiology, Treatment planning",
author = "Val Lowe and Hebert, {Mary E.} and Anscher, {Mitchell S.} and Coleman, {R. Edward}",
year = "1998",
doi = "10.1016/S1095-0397(98)00013-2",
language = "English (US)",
volume = "1",
pages = "185--191",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Serial evaluation of increased chest wall F-18 fluorodeoxyglucose (FDG) uptake following radiation therapy in patients with bronchogenic carcinoma

AU - Lowe, Val

AU - Hebert, Mary E.

AU - Anscher, Mitchell S.

AU - Coleman, R. Edward

PY - 1998

Y1 - 1998

N2 - Purpose: Following radiation therapy for bronchogenic carcinoma, increased FDG accumulation within the irradiated tissue can be identified. This finding has not been well characterized. Therefore, we retrospectively evaluated the time course, frequency, and intensity of increased FDG uptake over a one-year period in patients who had been treated with radiation therapy. Materials and Methods: Serial FDG-PET studies (n = 38) were performed in patients (n = 12) with bronchogenic carcinoma before and after radiation therapy. Regions of interest (ROIs) were placed in the chest wall and activity concentrations of posttherapy studies were compared to pretherapy studies. FDG uptake was also described qualitatively relative to mediastinal activity (1-4 scale) by two observers blinded from clinical information. Results: Chest wall radiation port ROI uptake was 18% higher in the 2-month (P = 0.08), 40% higher in the 6-month (P = 0.003), and 32% higher in the 12-month (P = 0.04) posttherapy studies than in non-port ROIs. In 6 patients that clinically had radiation-induced chest wall fibrosis or pneumonitis, visual interpretation identified abnormal chest wall or pleural region FDG uptake in 5/6. In 2/6 patients without clinical chest wall fibrosis, abnormal, chest wall FDG uptake was seen. Conclusions: Radiation therapy occasionally causes modestly increased soft tissue FDG uptake within irradiated soft tissue in patients being treated for bronchogenic carcinoma, which persists for up to one year after therapy.

AB - Purpose: Following radiation therapy for bronchogenic carcinoma, increased FDG accumulation within the irradiated tissue can be identified. This finding has not been well characterized. Therefore, we retrospectively evaluated the time course, frequency, and intensity of increased FDG uptake over a one-year period in patients who had been treated with radiation therapy. Materials and Methods: Serial FDG-PET studies (n = 38) were performed in patients (n = 12) with bronchogenic carcinoma before and after radiation therapy. Regions of interest (ROIs) were placed in the chest wall and activity concentrations of posttherapy studies were compared to pretherapy studies. FDG uptake was also described qualitatively relative to mediastinal activity (1-4 scale) by two observers blinded from clinical information. Results: Chest wall radiation port ROI uptake was 18% higher in the 2-month (P = 0.08), 40% higher in the 6-month (P = 0.003), and 32% higher in the 12-month (P = 0.04) posttherapy studies than in non-port ROIs. In 6 patients that clinically had radiation-induced chest wall fibrosis or pneumonitis, visual interpretation identified abnormal chest wall or pleural region FDG uptake in 5/6. In 2/6 patients without clinical chest wall fibrosis, abnormal, chest wall FDG uptake was seen. Conclusions: Radiation therapy occasionally causes modestly increased soft tissue FDG uptake within irradiated soft tissue in patients being treated for bronchogenic carcinoma, which persists for up to one year after therapy.

KW - F-18 fluorodeoxyglucose (FDG)

KW - Lung neoplasms

KW - Positron emission tomography (PET)

KW - Therapeutic radiology

KW - Treatment planning

UR - http://www.scopus.com/inward/record.url?scp=6044220154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044220154&partnerID=8YFLogxK

U2 - 10.1016/S1095-0397(98)00013-2

DO - 10.1016/S1095-0397(98)00013-2

M3 - Article

AN - SCOPUS:6044220154

VL - 1

SP - 185

EP - 191

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 3

ER -